The laparoscopic sleeve gastrectomy (LSG), or “lap sleeve,” is the most recent addition to the commonly performed metabolic surgeries. The procedure was first described in 1993 as a part of the biliopancreatic diversion and subsequently began to be employed as the first part of a staged duodenal switch in the 2000s. Soon it was recognized that results from the sleeve gastrectomy alone were adequate for many patients, and the sleeve gastrectomy is now the fastest growing segment of bariatric surgery [1].

The sleeve gastrectomy is considered primarily a restrictive technique; however, there is still ongoing research involving hormonal effects, with alterations of ghrelin production being cited most often. These factors produce excellent outcomes. Patients can expect to lose up to 75 % of excess body weight with a reduction in comorbidities ranging from diabetes mellitus to hypertension within the first year after surgery.